Disclosed and claimed are methods for making solid vaccine compositions that have reduced foaming when mixed with liquid diluent. The methods include mixing an effective amount of a foam controlling agent with at least one anhydrous antigenic component, a stabilizer, and an effervescent agent. The foam controlling agent is a sugar alcohol, such as mannitol. The effective amount of sugar alcohol is about 15% to about 40% by weight of the solid vaccine composition. And, upon adding a diluent to the solid vaccine composition, the effervescent agent reacts to form gas in situ, and foam resulting from the gas is reduced.

Disclosed and claimed are methods for making solid vaccine compositions that have reduced foaming when mixed with liquid diluent. The methods include mixing an effective amount of a foam controlling agent with at least one anhydrous antigenic component, a stabilizer, and an effervescent agent. The foam controlling agent is a sugar alcohol, such as mannitol. The effective amount of sugar alcohol is about 15% to about 40% by weight of the solid vaccine composition. And, upon adding a diluent to the solid vaccine composition, the effervescent agent reacts to form gas in situ, and foam resulting from the gas is reduced.

The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

The present invention relates to novel stable compressed vaccine composition comprising at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

Provided herein are compositions including a probiotic including at least one strain of live bacteria and a Marek's Disease vaccine. Compositions including a probiotic or a probiotic and a Marek's Disease vaccine may be administered to subjects, including poultry. The compositions may be administered in ovo to increase early lactic acid bacteria in the gastrointestinal tract of the subject, to decrease the gram negative bacteria in the gastrointestinal tract of the subject, to reduce the level of Salmonella in the gastrointestinal tract of the subject and to increase the body weight gain of the subject. Also provided are kits including a probiotic and a Marek's Disease vaccine.

Provided herein are compositions including a probiotic including at least one strain of live bacteria and a Marek's Disease vaccine. Compositions including a probiotic or a probiotic and a Marek's Disease vaccine may be administered to subjects, including poultry. The compositions may be administered in ovo to increase early lactic acid bacteria in the gastrointestinal tract of the subject, to decrease the gram negative bacteria in the gastrointestinal tract of the subject, to reduce the level of Salmonella in the gastrointestinal tract of the subject and to increase the body weight gain of the subject. Also provided are kits including a probiotic and a Marek's Disease vaccine.

The present invention provides an effective vaccine for Marek's disease, which may be prepared using a recombinant Marek's Disease Virus (MDV), strain CVI988, having been transformed with a foreign DNA construct that includes a long terminal repeat sequence of a reticuloendotheliosis virus. This safe viral agent elicits a highly protective immune response in a chicken against virulent MDV challenge without causing a significant degree of pathogenicity. Suitable formulations of the vaccine for use in chickens include an effective immunization dosage of this novel viral agent, along with a pharmaceutically acceptable carrier or diluent.

The present invention provides an effective vaccine for Marek's disease, which may be prepared using a recombinant Marek's Disease Virus (MDV), strain CVI988, having been transformed with a foreign DNA construct that includes a long terminal repeat sequence of a reticuloendotheliosis virus. This safe viral agent elicits a highly protective immune response in a chicken against virulent MDV challenge without causing a significant degree of pathogenicity. Suitable formulations of the vaccine for use in chickens include an effective immunization dosage of this novel viral agent, along with a pharmaceutically acceptable carrier or diluent.

The present invention relates to novel stable compressed vaccine composition composing at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.

The present invention relates to novel stable compressed vaccine composition composing at least one anhydrous antigenic component comprising a stabilizer susceptible to foaming when the composition is mixed with liquid diluent; and an effective amount of a sugar alcohol.